Search

Ganapathy N Sarma

from Belmont, MA
Age ~48

Ganapathy Sarma Phones & Addresses

  • 60 Creeley Rd, Belmont, MA 02478
  • San Ramon, CA
  • Sunnyvale, CA
  • 8020 Avenida Navidad, San Diego, CA 92122 (858) 202-0588
  • 2310 Rolling Green Dr, Corvallis, OR 97330 (541) 753-3759
  • La Jolla, CA

Publications

Us Patents

Anti-Cd117 Antibody-Drug Conjugates And Uses Thereof

View page
US Patent:
20220175944, Jun 9, 2022
Filed:
Oct 21, 2021
Appl. No.:
17/507618
Inventors:
- Cambridge MA, US
Anthony Boitano - Newton MA, US
Michael Cooke - Boston MA, US
Ganapathy N. Sarma - Belmont MA, US
Rajiv Panwar - Acton MA, US
International Classification:
A61K 47/68
C07K 16/28
A61K 47/65
A61K 35/28
Abstract:
Anti-CD117 antibody-drug conjugates (ADCs) comprising pyrrolobenzodiazepine are provided, as well as compositions and methods of using the same. The compositions and methods provided herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure. Methods and compositions for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, are provided.

Anti-Cd117 Antibody Drug Conjugates And Uses Thereof

View page
US Patent:
20220177577, Jun 9, 2022
Filed:
Oct 22, 2021
Appl. No.:
17/508759
Inventors:
- Cambridge MA, US
Anthony Boitano - Newton MA, US
Michael Cooke - Boston MA, US
Ganapathy N. Sarma - Belmont MA, US
Rajiv Panwar - Acton MA, US
International Classification:
C07K 16/28
A61K 47/68
A61P 35/00
Abstract:
Anti-CD117 antibody-drug conjugates (ADCs) comprising calicheamicin and are provided, as well as compositions and methods of using the same. The compositions and methods provided herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure. Methods and compositions for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, are provided.

Amatoxin Antibody-Drug Conjugates And Uses Thereof

View page
US Patent:
20200407440, Dec 31, 2020
Filed:
Apr 24, 2020
Appl. No.:
16/858509
Inventors:
- Cambridge MA, US
Rajiv Panwar - Acton MA, US
Ganapathy N. Sarma - Belmont MA, US
Torsten Hechler - Ladenburg, DE
Michael Kulke - Ladenburg, DE
Andreas Pahl - Ladenburg, DE
Christoph Mueller - Ladenburg, DE
Werner Simon - Ladenburg, DE
Christian Lutz - Ladenburg, DE
Francesca Gallo - Ladenburg, DE
International Classification:
C07K 16/28
A61K 45/06
A61K 47/68
Abstract:
Amatoxins, as well as antibody-drug conjugates (ADCs) comprising an amatoxin are provided, as well as compositions and methods of using the same. The compositions and methods provided herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure. Methods and compositions for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, as well as prevention of graft-versus-host-disease (GVHD), are provided.

Fc Silenced Antibody Drug Conjugates (Adcs) And Uses Thereof

View page
US Patent:
20200376135, Dec 3, 2020
Filed:
Apr 24, 2020
Appl. No.:
16/858481
Inventors:
- Cambridge MA, US
Michael Cooke - Brookline MA, US
Charlotte Fenton McDonagh - Winchester MA, US
Rahul Palchaudhuri - Somerville MA, US
Bradley R. Pearse - Watertown MA, US
Ganapathy N. Sarma - Belmont MA, US
Assignee:
Magenta Therapeutics, Inc. - Cambridge MA
International Classification:
A61K 47/68
C07K 16/28
Abstract:
Disclosed are antibodies and antibody drug conjugates having an Fc region with substitutions resulting in essentially a silent Fc region. The antibodies and antibody drug conjugates described herein are useful for the depletion of cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting, e.g., a population of CD45+ or CD117+ cancer cells or CD45+ autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.

Fc Silenced Antibody Drug Conjugates (Adcs) And Uses Thereof

View page
US Patent:
20200255523, Aug 13, 2020
Filed:
Apr 30, 2020
Appl. No.:
16/863948
Inventors:
- Cambridge MA, US
Anthony Boitano - Newton MA, US
Charlotte Fenton McDonagh - Winchester MA, US
Bradley R. Pearse - Watertown MA, US
Ganapathy N. Sarma - Belmont MA, US
International Classification:
C07K 16/28
A61K 47/68
Abstract:
Disclosed are antibodies and antibody drug conjugates having an Fc region with substitutions resulting in essentially a silent Fc region. The antibodies and antibody drug conjugates described herein are useful for the depletion of cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting, e.g., a population of CD45+ or CD117+ cancer cells or CD45+ autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.

Transglutaminase Variants For Conjugating Antibodies

View page
US Patent:
20180265851, Sep 20, 2018
Filed:
Sep 30, 2016
Appl. No.:
15/763677
Inventors:
- Princeton NJ, US
Ganapathy N. SARMA - San Ramon CA, US
Akbar NAYEEM - Newtown PA, US
International Classification:
C12N 9/10
C12P 21/00
A61K 47/68
Abstract:
Transglutaminase variants capable of conjugating an antibody that is not conjugated by wild-type transglutaminase from
Ganapathy N Sarma from Belmont, MA, age ~48 Get Report